• Wenting Xu, Hanyue Dong, Haolong Ran, Huan Liu, Lin Wang, Hongmin Li, and Cheng Tan.
• Department of Dermatology, (W.X., H.D., H.L.R., H.L., H.L., C.T.) Affiliated Hospital of Nanjing University of Chinese Medicine 155 Hanzhong Road, Nanjing 210029, China.
• J Pain Symptom Manage. 2025 Jan 1; 69 (1): 658165-81.

ContextLimited data existed on the efficacy and safety of novel antiepileptic drugs (pregabalin and gabapentin) in treating pruritus.ObjectivesTo assess their role in managing either acute or chronic pruritus.MethodsA systematic search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science databases for relevant randomized controlled trials. Pooled odd ratio (OR) with 95% CI were performed using RevMan5.4 and R4.3.1.ResultsAnalysis of 27 articles involving 2,016 patients showed significant reduction in pruritus incidence (OR, 0.30 [CI, 0.22-0.4]; I2=1%) and improvements in VAS (MD, 2.76 [CI, 0.95-4.57]; I2=98%) and 5-D scores (MD, 3.42 [CI, 2.10-4.75]; I2=92%) with pregabalin/gabapentin compared to controls. Adverse effects mainly included dizziness, somnolence, nausea and vomiting, dry mouth, constipation, and anxiety, with no significant difference between the groups (OR, 1.08 [CI, 0.32-3.59]; I2=76%).ConclusionThe novel antiepileptic drugs pregabalin and gabapentin demonstrated significant therapeutic value in the treatment of pruritus, with a favorable safety profile. Compared to commonly used pruritus treatments such as antihistamines and antidepressants, these medications offered a promising alternative.Copyright © 2024 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

18 keywords...

hide…